市場調査レポート

商品コード

1622325

網膜疾患治療の市場規模、シェア、成長分析、疾患別、障害の種類別、治療技術別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2024～2031年

Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Disorder, By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日: 2024年12月23日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

網膜疾患治療2023年の市場規模は125億7,000万米ドルで、2024年の137億4,000万米ドルから2032年には280億8,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは9.3%で推移する見通しです。

網膜障害の有病率は世界的に高まっており、2億5,300万人以上が影響を受け、特に人口の高齢化に伴ってヘルスケアシステムに重大な課題をもたらしています。罹患者の81%が50歳以上であり、平均寿命の延びが眼科医療分野の需要を高めています。網膜疾患、特に糖尿病性網膜症や糖尿病性黄斑浮腫の発症率は、特に糖尿病罹患率が増加している新興諸国において急増しています。これらの疾患に対応できる専門家の数が増加していることもあり、市場は予測期間中に拡大すると予想されます。さらに、償還政策の強化は、網膜疾患治療に関連する高コストを支援し、2028年までに市場成長を促進すると予想されます。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
市場の最近の動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 会社概要
- 製品ポートフォリオ分析
- セグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Regeneron Pharmaceuticals, Inc.（USA）
Roche Holding AG（Switzerland）
Novartis AG（Switzerland）
Allergan（part of AbbVie）（USA）
Bayer AG（Germany）
Oculis（Switzerland）
REGENXBIO Inc.（USA）
Adverum Biotechnologies, Inc.（USA）
Kodiak Sciences Inc.（USA）
EyePoint Pharmaceuticals, Inc.（USA）
Apellis Pharmaceuticals, Inc.（USA）
Iveric Bio, Inc.（USA）（Acquired by Astellas）
Annexon Biosciences（USA）
Hemera Biosciences（USA）（Acquired by Roche）
Gyroscope Therapeutics（UK）（Acquired by Novartis）
Graybug Vision, Inc.（USA）
Clearside Biomedical, Inc.（USA）
Ocuphire Pharma, Inc.（USA）
Lineage Cell Therapeutics, Inc.（USA）
Ocugen, Inc.（USA）

結論と推奨事項

Product Code: SQMIG35H2062

Retinal Disease Therapeutics Market size was valued at USD 12.57 Billion in 2023 and is poised to grow from USD 13.74 Billion in 2024 to USD 28.08 Billion by 2032, growing at a CAGR of 9.3% during the forecast period (2025-2032).

The prevalence of retinal disorders is escalating globally, impacting over 253 million people and posing significant challenges for healthcare systems, particularly as the population ages. With 81% of individuals affected being over 50, the rising life expectancy is intensifying demand in the ophthalmic care sector. The incidence of retinal diseases, notably diabetic retinopathy and diabetic macular edema, is surging, especially in developing countries where diabetes rates are increasing. The market is anticipated to expand during the forecast period, driven by the growing number of specialized professionals capable of addressing these conditions. Furthermore, enhanced reimbursement policies are expected to facilitate market growth by 2028, assisting with the high costs associated with retinal disease treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disease Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disease Therapeutics Market Segmental Analysis

Global Retinal Disease Therapeutics Market is segmented by disorder, disorder type, treatment techniques, route of administration, end-users, distribution channel and region. Based on disorder, the market is segmented into macular degeneration, diabetic eye disease, retinal detachment, retinoblastoma, macular pucker, macular hole and floaters. Based on disorder type, the market is segmented into genetic and age related. Based on treatment techniques, the market is segmented into laser, freezing, implanting, indenting, pneumatic retinopexy, scleral buckling and vitrectomy. Based on route of administration, the market is segmented into oral, topical, intravitreal and others. Based on end-users, the market is segmented into hospitals, ambulatory surgical centers, home healthcare and others. Based on distribution channel, the market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Disease Therapeutics Market

The growth of the retinal disease therapeutics market is significantly influenced by the rising prevalence of eye disorders, especially in developed nations. Notably, the American Academy of Ophthalmology reported that as of 2016, around 93 million people globally were affected by diabetic retinopathy, with 4.2 million cases in the United States alone. Projections by the NCBI estimate that by 2040, Europe could see between 14.9 to 21.5 million individuals with early Age-Related Macular Degeneration (AMD) and up to 4.8 million with late-stage AMD. Efforts to raise awareness about eye health and encourage early treatment, particularly in developing regions, are expected to further propel the growth of the retinal disease therapeutics market in the upcoming years.

Restraints in the Retinal Disease Therapeutics Market

The growth of the Retinal Disease Therapeutics market faces several challenges, primarily due to the high costs associated with treatment options for retinal diseases. The financial burden of these therapies can deter patients from seeking necessary care. Furthermore, patients often report experiencing short-term side effects, as well as potential long-term issues like infections and inflammation following procedures like laser eye surgery. Surgical techniques, such as pneumatic retinopexy, carry risks, including unintended scleral perforation, which may further influence patient choices. Additionally, inadequate healthcare infrastructure in developing countries poses significant barriers to market expansion, limiting access to effective therapies.

Market Trends of the Retinal Disease Therapeutics Market

The retinal disease therapeutics market is witnessing a significant upward trend, fueled by the emergence of advanced technologies such as gene therapy. Innovations like Luxturna, targeting inherited retinal disorders through RPE65 gene mutations, exemplify the progress being made in this field. As numerous gene therapies involving recombinant viral vectors advance through clinical trials, their potential to ameliorate conditions like Leber's congenital amaurosis is garnering attention and investment. Between 2022 and 2028, this focus on high-end therapeutic solutions is expected to drive market growth, paving the way for improved treatment outcomes and enhanced quality of life for patients suffering from retinal diseases.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Retinal Disease Therapeutics Market Size by Disorder & CAGR (2025-2032)

Market Overview
Macular Degeneration
Diabetic Eye Disease
Retinal Detachment
Retinoblastoma
Macular Pucker
Macular Hole
Floaters

Global Retinal Disease Therapeutics Market Size by Disorder Type & CAGR (2025-2032)

Market Overview
Genetic
Age Related

Global Retinal Disease Therapeutics Market Size by Treatment Techniques & CAGR (2025-2032)

Market Overview
Laser
Freezing
Implanting
Indenting
Pneumatic Retinopexy
Scleral Buckling
Vitrectomy

Global Retinal Disease Therapeutics Market Size by Route Of Administration & CAGR (2025-2032)

Market Overview
Oral
Topical
Intravitreal
Others

Global Retinal Disease Therapeutics Market Size by End-Users & CAGR (2025-2032)

Market Overview
Hospitals
Ambulatory Surgical Centers
Home Healthcare
Others

Global Retinal Disease Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

Market Overview
Direct Tender
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Global Retinal Disease Therapeutics Market Size & CAGR (2025-2032)

North America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- US
- Canada
Europe (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Disorder, Disorder Type, Treatment Techniques, Route Of Administration, End-Users, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Regeneron Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (part of AbbVie) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oculis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
REGENXBIO Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EyePoint Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apellis Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Iveric Bio, Inc. (USA) (Acquired by Astellas)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Annexon Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemera Biosciences (USA) (Acquired by Roche)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gyroscope Therapeutics (UK) (Acquired by Novartis)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocuphire Pharma, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lineage Cell Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocugen, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

網膜疾患治療の市場規模、シェア、成長分析、疾患別、障害の種類別、治療技術別、投与経路別、エンドユーザー別、流通チャネル別、地域別 - 産業予測、2024～2031年

Retinal Disease Therapeutics Market Size, Share, Growth Analysis, By Disorder, By Disorder Type, By Treatment Techniques, By Route Of Administration, By End-Users, By Distribution Channel, By Region - Industry Forecast 2024-2031

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

網膜疾患治療市場規模：疾患別

網膜疾患治療市場規模：障害の種類別

網膜疾患治療市場規模：治療技術別

網膜疾患治療市場規模：投与経路別

網膜疾患治療市場規模：エンドユーザー別

網膜疾患治療市場規模：流通チャネル別

網膜疾患治療の市場規模